Literature DB >> 24534109

Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation.

Craig S Sauter1, Lauren Lechner2, Michael Scordo3, Junting Zheng4, Sean M Devlin4, Stephen E Fleming5, Hugo Castro-Malaspina6, Craig H Moskowitz6.   

Abstract

Whether chemosensitivity, as determined by positron emission tomography using fluorine-18-deoxyglucose (FDG-PET), is a requirement for successful allogeneic hematopoietic stem cell transplantation (allo-SCT) has yet to be established. We analyzed 88 patients with B cell non-Hodgkin lymphoma (B-NHL) for event-free (EFS) and overall survival (OS) according to computed tomography (CT) and FDG-PET criteria before uniform nonmyeloablative (NMA) allo-SCT. Patients who were chemosensitive, according to CT criteria, experienced significantly greater EFS (P < .001) and OS (P < .03) compared with those who were chemorefractory at the time of allo-SCT. Of 58 patients within this cohort who were chemosensitive by CT criteria, there was no difference in EFS (P = .85) or OS (P = .96) between FDG-PET-positive (Deauville 4 to 5, n = 24) and FDG-PET-negative (Deauville 1 to 3, n = 34) patients. There was no difference in survival according to age < or ≥ 60 years, prior autologous-stem cell transplantation, allograft characteristics, or histology. FDG-PET adds no prognostic value in chemosensitive B-NHL before NMA-allo-SCT.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic transplant; B cell non-Hodgkin lymphoma; Fluorine-18-deoxyglucose–Positron emission tomography (FDG-PET) scan

Mesh：

Substances：

Year:  2014        PMID： 24534109      PMCID： PMC5716350          DOI： 10.1016/j.bbmt.2014.02.009

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  21 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.

Authors:  J B Cohen; N C Hall; A S Ruppert; J A Jones; P Porcu; R Baiocchi; B A Christian; S Penza; D M Benson; J Flynn; L A Andritsos; S M Devine; K A Blum
Journal:  Bone Marrow Transplant       Date:  2013-04-15       Impact factor: 5.483

3.  Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus.

Authors:  Michel Meignan; Andrea Gallamini; Emmanuel Itti; Sally Barrington; Corinne Haioun; Aaron Polliack
Journal:  Leuk Lymphoma       Date:  2012-04-23

4.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

5.  Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation.

Authors:  Anna Dodero; Roberto Crocchiolo; Francesca Patriarca; Rosalba Miceli; Luca Castagna; Fabio Ciceri; Stefania Bramanti; Niccolo Frungillo; Raffaella Milani; Flavio Crippa; Federico Fallanca; Emanuela Englaro; Paolo Corradini
Journal:  Cancer       Date:  2010-11-01       Impact factor: 6.860

6.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

Authors:  Christian Gisselbrecht; Bertram Glass; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Nicolas Ketterer; Ofer Shpilberg; Hans Hagberg; David Ma; Josette Brière; Craig H Moskowitz; Norbert Schmitz
Journal:  J Clin Oncol       Date:  2010-07-26       Impact factor: 44.544

7.  Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.

Authors:  Jonathan R Lambert; Jamshed B Bomanji; Karl S Peggs; Kirsty J Thomson; Ronjon K Chakraverty; Adele K Fielding; Panagiotis D Kottaridis; Michael Roughton; Emma C Morris; Anthony H Goldstone; David C Linch; Peter J Ell; Stephen Mackinnon
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

8.  Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Authors:  Stéphane Vigouroux; Mauricette Michallet; Raphaël Porcher; Michel Attal; Lionel Ades; Marc Bernard; Didier Blaise; Reza Tabrizi; Frédéric Garban; Jill-Patrice Cassuto; Patrice Chevalier; Thierry Facon; Norbert Ifrah; Marc Renaud; Hervé Tilly; Jean-Paul Vernant; Mathieu Kuentz; Jean-Henri Bourhis; Pierre Bordigoni; Eric Deconinck; Bruno Lioure; Gérard Socié; Noël Milpied
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

9.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

10.  Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.

Authors:  Kirsty J Thomson; Emma C Morris; Adrian Bloor; Gordon Cook; Don Milligan; Anne Parker; Fiona Clark; Lynny Yung; David C Linch; Ronjon Chakraverty; Karl S Peggs; Stephen Mackinnon
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544
View more
  8 in total

1.  Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan has no influence on relapse and survival in non-Hodgkin lymphoma patients undergoing allo-SCT.

Authors:  V Bachanova; Q Cao; C Ustun; A T K Kendi; J Froelich; A Lazaryan; L J Burns
Journal:  Bone Marrow Transplant       Date:  2014-09-29       Impact factor: 5.483

2.  Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.

Authors:  Craig S Sauter; Matthew J Matasar; Jessica Meikle; Heiko Schoder; Gary A Ulaner; Jocelyn C Migliacci; Patrick Hilden; Sean M Devlin; Andrew D Zelenetz; Craig H Moskowitz
Journal:  Blood       Date:  2015-03-10       Impact factor: 22.113

3.  Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.

Authors:  Gary A Ulaner; Debra A Goldman; Craig S Sauter; Jocelyn Migliacci; Joshua Lilienstein; Mithat Gönen; Heiko Schöder; Craig H Moskowitz; Andrew D Zelenetz
Journal:  Radiology       Date:  2015-06-02       Impact factor: 11.105

4.  Evolution of lymphoma staging and response evaluation: current limitations and future directions.

Authors:  Joel Cunningham; Sunil Iyengar; Bhupinder Sharma
Journal:  Nat Rev Clin Oncol       Date:  2017-06-13       Impact factor: 66.675

5.  Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.

Authors:  Veronika Bachanova; Linda J Burns; Kwang Woo Ahn; Ginna G Laport; Görgün Akpek; Mohamed A Kharfan-Dabaja; Taiga Nishihori; Edward Agura; Philippe Armand; Samantha M Jaglowski; Mitchell S Cairo; Amanda F Cashen; Jonathon B Cohen; Anita D'Souza; César O Freytes; Robert Peter Gale; Siddhartha Ganguly; Nilanjan Ghosh; Leona A Holmberg; David J Inwards; Abraham S Kanate; Hillard M Lazarus; Adriana K Malone; Reinhold Munker; Alberto Mussetti; Maxim Norkin; Tim D Prestidge; Jacob M Rowe; Prakash Satwani; Tanya Siddiqi; Patrick J Stiff; Basem M William; Baldeep Wirk; David G Maloney; Sonali M Smith; Anna M Sureda; Jeanette Carreras; Mehdi Hamadani
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-14       Impact factor: 5.742

6.  The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.

Authors:  Matthew A Lunning; Jocelyn C Migliacci; Patrick Hilden; Sean M Devlin; Hugo Castro-Malaspina; Sergio Giralt; Miguel-Angel Perales; Andrew D Zelenetz; Craig H Moskowitz; Craig S Sauter
Journal:  Br J Haematol       Date:  2016-02-05       Impact factor: 6.998

7.  Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era.

Authors:  Craig S Sauter; Miguel-Angel Perales; Alberto Mussetti; Sean M Devlin; Hugo R Castro-Malaspina; Juliet N Barker; Sergio A Giralt; Andrew D Zelenetz
Journal:  Bone Marrow Transplant       Date:  2015-07-06       Impact factor: 5.483

8.  Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival.

Authors:  Na Dai; Hang Liu; Shengming Deng; Shibiao Sang; Yiwei Wu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.